Treatment of ventilator-associated pneumonia (VAP) caused by Acinetobacter: results of prospective and multicenter ID-IRI study
Ventilator-associated pneumonia (VAP) due to Acinetobacter spp. is one of the most common infections in the intensive care unit. Hence, we performed this prospective-observational multicenter study, and described the course and outcome of the disease. This study was performed in 24 centers between January 06, 2014, and December 02, 2016. The patients were evaluated at time of pneumonia diagnosis, when culture results were available, and at 72 h, at the 7th day, and finally at the 28th day of follow-up. Patients with coexistent infections were excluded and only those with a first VAP episode were enrolled. Logistic regression analysis was performed. A total of 177 patients were included; empiric antimicrobial therapy was appropriate (when the patient received at least one antibiotic that the infecting strain was ultimately shown to be susceptible) in only 69 (39%) patients. During the 28-day period, antibiotics were modified for side effects in 27 (15.2%) patients and renal dose adjustment was made in 38 (21.5%). Ultimately, 89 (50.3%) patients died. Predictors of mortality were creatinine level (OR, 1.84 (95% CI 1.279–2.657); p = 0.001), fever (OR, 0.663 (95% CI 0.454–0.967); p = 0.033), malignancy (OR, 7.095 (95% CI 2.142–23.500); p = 0.001), congestive heart failure (OR, 2.341 (95% CI 1.046–5.239); p = 0.038), appropriate empiric antimicrobial treatment (OR, 0.445 (95% CI 0.216–0.914); p = 0.027), and surgery in the last month (OR, 0.137 (95% CI 0.037–0.499); p = 0.003). Appropriate empiric antimicrobial treatment in VAP due to Acinetobacter spp. was associated with survival while renal injury and comorbid conditions increased mortality. Hence, early diagnosis and appropriate antibiotic therapy remain crucial to improve outcomes.
KeywordsVentilator-associated pneumonia VAP Pneumonia Acinetobacter Mortality Treatment
Infectious Diseases and Clinical Microbiology Specialty Society of Turkey (EKMUD) provided the web infrastructure of the study for data submission.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
Dr. Lutfi Kirdar Education and Training Hospital’s Review Board in Istanbul approved the study (02/01/2014-VIP 2014/1) and this approval was confirmed the Turkish Ministry of Health, Drugs and Pharmaceutics Agency for all participating centers. This study was performed in accordance with the Helsinki Declaration of 1964 and its later amendments.
Yes, informed consent is obtained.
- 1.Magill SS, Edwards JR, Bamberg W, Beldavs ZG, Dumyati G, Kainer MA et al (2014) Multistate point-prevalence survey of health care–associated infections. N Engl J Med 370:1198–1208. [cited 2018 6]. http://www.ncbi.nlm.nih.gov/pubmed/24670166. https://doi.org/10.1056/NEJMoa1306801 CrossRefGoogle Scholar
- 2.Erdem H, Inan A, Altindis S, Carevic B, Askarian M, Cottle L et al (2014) Surveillance, control and management of infections in intensive care units in southern Europe, Turkey and Iran - a prospective multicenter point prevalence study. J Inf Secur 68:131–140. https://doi.org/10.1016/j.jinf.2013.11.001 Google Scholar
- 3.Kalil AC, Metersky ML, Klompas M, Muscedere J, Sweeney DA, Palmer LB, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis 2016;63:e61–111. doi: https://doi.org/10.1093/cid/ciw353
- 6.Erdem H, Dizbay M, Karabey S, Kaya S, Demirdal T, Koksal I, et al. (2013) Withdrawal of Staphylococcus aureus from intensive care units in Turkey. Am J Infect Control 41. doi: https://doi.org/10.1016/j.ajic.2013.01.041
- 7.Asif M, Alvi IA, Rehman SU (2018) Infection and drug resistance. Dovepress. Insight into Acinetobacter baumannii: pathogenesis, global resistance, mechanisms of resistance, treatment options, and alternative modalities. 1249–60. doi: https://doi.org/10.2147/IDR.S166750doi:10.2147/IDR.S166750
- 8.Bonell A, Azarrafiy R, Huong TVL, Viet TL, Phu VD et al (2018;doi: http://fdslive.oup.com/www.oup.com/pdf/production_in_progress.pdf) A systematic review and meta-analysis of ventilator associated pneumonia in adults in Asia: an analysis of national income level on incidence and etiology. Clin Infect Dis. https://doi.org/10.11821/dlxb201802008
- 9.The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 4.0. 2014Google Scholar
- 10.The European committee on antimicrobial susceptibility testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 5.0 [Internet]. 2015. doi: http://www.eucast.org
- 11.The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters, version 6.0. 2016Google Scholar
- 12.Magiorakos A-P, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG et al (2011) Bacteria : an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 18:268–281. http://onlinelibrary.wiley.com/doi/10.1111/j.1469-0691.2011.03570.x/full. https://doi.org/10.1111/j.1469-0691.2011.03570.x CrossRefGoogle Scholar
- 13.Centers for Disease Control and Prevention (2019) (Ventilator-associated pneumonia [VAP] and non-ventilator-associated pneumonia [PNEU]) event. Device-associated module. CDC;1–16Google Scholar
- 18.Vazquez Guillamet C, Kollef MH (2018) Acinetobacter pneumonia: improving outcomes with early identification and appropriate therapy. Clin Infect Dis 67:1455–1462. https://academic.oup.com/cid/article/67/9/1455/4993159. https://doi.org/10.1093/cid/ciy375 CrossRefGoogle Scholar
- 19.Isler B, Doi Y, Bonomo RA, Paterson DL (2018) New treatment options against carbapenem-resistant Acinetobacter baumannii infections. Antimicrob Agents Chemother ;1–43. doi: http://aac.asm.org/lookup/doi/10.1128/AAC.01110-18 doi: https://doi.org/10.1128/AAC.01110-18
- 20.Freire AT, Melnyk V, Kim MJ, Datsenko O, Dzyublik O, Glumcher F et al (2010) Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia. Diagn Microbiol Infect Dis 68:140–151. https://doi.org/10.1016/j.diagmicrobio.2010.05.012 CrossRefGoogle Scholar
- 22.Huang AM, Newton D, Kunapuli A, Gandhi TN, Washer LL, Isip J et al (2013) Impact of rapid organism identification via matrix-assisted laser desorption/ionization time-of-flight combined with antimicrobial stewardship team intervention in adult patients with bacteremia and candidemia. Clin Infect Dis 57:1237–1245. https://doi.org/10.1093/cid/cit498 CrossRefGoogle Scholar